Strategic Partnerships FluidForm Bio's FRESH living-tissue platform, built with 3D printing, computational biology, AI, and advanced materials science, is positioned for co-development with pharma and biotech customers. With validated tissue across multiple applications and active partnerships, there is a clear path to secure tissue-modeling deals, drug-screening collaborations, and CRO engagements.

Mid-Market Focus As a lean company, FluidForm Bio is well suited to engage mid-market biotech firms and contract research organizations that need high-quality tissue models but lack in-house capabilities. Opportunities include research collaborations, licensing of FRESH technology, or contract development to accelerate drug programs.

Differentiated Platform The tissue is described as indistinguishable from real human tissue and is enabled by 3D printing, synthetic biology, and AI, offering potentially higher predictive value in drug screening, toxicology, and precision medicine. This differentiates FluidForm Bio to target early discovery labs, toxicology groups, and translational researchers seeking more accurate models.

Regional Focus Based in Waltham, Massachusetts, FluidForm Bio sits in the Boston biotech corridor, enabling proximity to top universities, hospitals, and pharma campuses for pilots and site collaborations. Attendance at industry events like Biotech Showcase and LifeSci Partners Corporate Access signals an active business development outreach strategy.

Growth Opportunities With a scalable platform and ongoing partnerships, FluidForm Bio is well positioned to pursue licensing, co-development, and multi-site deployment opportunities to scale tissue production and broaden applications.